Long-term evolocumab therapy leads to further reductions in cardiovascular events
Long-term low-density lipoprotein (LDL) cholesterol lowering with evolocumab is safe and well tolerated and leads to further reductions in cardiovascular events compared with shorter treatment, according to late breaking ...
Aug 29, 2022
0
7